Company: PTPI
Filing Date: 2025-02-21
Form Type: 8-K
Source: 0001104659-25-016181
Chunk: 0

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-21
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material Definitive
Agreement

On February 17, 2025, Petros Pharmaceuticals, Inc.
(the “ Company”) entered into a securities purchase agreement (the “ Purchase Agreement”) with certain institutional
and accredited investors (collectively, the “ Investors”) for the issuance and sale, in a best efforts public offering (the
“ Offering”), of (i) 13,950,012 units (the “ Units”), each Unit consisting of one share (the “ Shares”)
of the Company’s common stock, par value $0.0001 per share (the “ Common Stock”), one Series A Warrant (the “ Series A
Warrants”) to purchase 0.25 share of Common Stock (the “ Series A Warrant Shares”) and one Series B Warrant
(the “ Series B Warrants,” and together with the Series A Warrants, the “ Warrants”) to purchase one shares
of Common Stock (the “ Series B Warrant Shares” and, together with the Series A Warrant Shares, the “ Warrant
Shares”) and (ii) 26,049,988 pre-funded units (the “ Pre-Funded Units”), each Pre-Funded Unit consisting of one
pre-funded warrant (the “ Pre-Funded Warrants”) to purchase one share of Common Stock (the “ Pre-Funded Warrant Shares”),
one Series A Warrant and one Series B Warrant. The public offering price was $0.24 per Unit and $0.2399 per Pre-Funded Unit.
The Offering closed on February 19, 2025. The exercise price of each of the Series A Warrants and the Series B Warrants
is $0.48 per share of Common Stock.

The exercisability of the Warrants will be available
only upon receipt of such stockholder approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market
LLC, including, but not limited to, with respect to (i) the issuance of all of the shares of Common Stock issuable upon exercise
the Warrants in accordance with their terms (including adjustment provisions set forth therein), and (ii) to consent to any adjustment
to the exercise price or number of shares of Common Stock underlying the Warrants in the event of a Share Combination Event and Dilutive
Issuance, each as defined in the Warrants (collectively, the “ Warrant Stockholder Approval”). The Company has agreed to use